TRIM21 and myositis disease: Our observations were consistent with previous studies demonstrating that serum levels of anti-Ro52 antibodies are linked to activity and/or severity of multiple disease manifestations in anti-Jo-1 antibody-positive individuals that include myositis, xerophthalmia/xerostomia, and ILD (37).